[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cervical-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cervical-neoplasms":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":35,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100643560","phase-2-an-exploratory-study-of-zanidatamab-in-her2-positive-advanced-tumor-after-at-least-one-line-of-standard-therapy-100643560",false,"NCT07631871","An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy","Inclusion Criteria:\n\n1. Male or female subjects aged ≥ 18 years old.\n2. Subjects with locally advanced, unresectable or metastatic solid tumors who have progressed after ≥1 prior systemic therapy for advanced\u002Fmetastatic disease, or have no available optimal alternative treatments. Qualified tumor types include but are not limited to endometrial carcinoma, urothelial carcinoma, pancreatic cancer, colorectal carcinoma (CRC), head and neck adenocarcinoma (salivary gland adenocarcinoma, lacrimal gland adenocarcinoma, adenocarcinoma of unknown primary of the neck), cervical cancer, ovarian cancer and adenocarcinoma of unknown primary. Biliary tract malignancy, lung cancer and breast cancer are excluded. For CRC patients: documented RAS status (wild-type or mutant) and wild-type BRAF; prior treatment regimen should contain fluoropyrimidine, oxaliplatin and irinotecan unless contraindicated; anti-VEGF therapy when clinically indicated; anti-PD-L1 therapy for MSI-H\u002FdMMR tumors if clinically indicated.\n3. ECOG Performance Status 0, 1 or 2.\n4. Confirmed HER2 positivity defined as IHC 3+, or IHC 2+ with positive FISH amplification (per GC criteria).\n5. Willing and capable of providing adequate tumor specimens for central pathological re-assessment of HER2 status at institutional pathology department. Patients previously treated with HER2-ADC must provide FFPE tumor samples collected after last HER2-ADC administration. Specimens with insufficient tumor cellularity and fine-needle aspiration samples are not acceptable for HER2 testing.\n6. At least one measurable lesion at baseline per RECIST 1.1 criteria.\n7. Adequate bone marrow and organ function confirmed within 14 days prior to enrollment: Hemoglobin ≥ 9 g\u002FdL; Platelet count ≥ 75,000\u002Fmm³; Absolute neutrophil count (ANC) ≥ 1000\u002Fmm³; Serum albumin ≥ 2.5 g\u002FdL; PT, aPTT and INR ≤ 1.5 × ULN; AST\u002FALT ≤ 3 × ULN; ≤5 × ULN for subjects with liver metastasis; Total bilirubin ≤1.5 × ULN (no liver metastasis); ≤3 × ULN (baseline Gilbert syndrome or liver metastasis); Creatinine clearance ≥30 mL\u002Fmin (calculated by Cockcroft-Gault formula)\n8. LVEF ≥50% evaluated via echocardiogram (ECHO) or MUGA scan within 28 days before enrollment.\n\nExclusion Criteria:\n\nSubjects with any of the following conditions are ineligible:\n\n1. Documented spinal cord compression, leptomeningeal disease or clinically active central nervous system (CNS) metastasis.\n2. Active primary immunodeficiency, confirmed HIV infection, active HBV or HCV infection.\n3. History of non-infectious interstitial lung disease (ILD)\u002Fnon-infectious pneumonia requiring steroid therapy, ongoing active ILD\u002Fnon-infectious pneumonia, or suspected ILD\u002Fnon-infectious pneumonia that cannot be ruled out by screening imaging.\n4. History of myocardial infarction, symptomatic congestive heart failure (CHF, NYHA Class II-IV), unstable angina, or any cardiovascular event (including stroke) within 6 months prior to enrollment.\n5. Pulmonary exclusion items: (a) Clinically significant underlying pulmonary disorders, including but not limited to pulmonary embolism within 3 months before screening, severe asthma, severe COPD, restrictive lung disease, recurrent pleural effusion; (b) Confirmed autoimmune, connective tissue or inflammatory diseases (rheumatoid arthritis, Sjögren's syndrome, sarcoidosis etc.), or suspected pulmonary involvement at screening; full disease details shall be recorded in eCRF for enrolled subjects; (c) Previous total pneumonectomy.\n6. Confirmed presence of HER2 gene mutation.","ALL","18 Years",{"count":18,"type":19},10,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","The goal of this clinical trial is to learn if Zanidatamab can treat HER2-positive advanced tumors in adults. The main question it aims to answer is: What is the objective response rate of Zanidatamab in adult patients with HER-2 positive advanced solid tumors? Participants will receive Zanidatamab intravenously on Day 1 of each 2-week treatment cycle. The dosage is 20 mg\u002Fkg per cycle.",[25,26,27,28,29,30,31,32,33,34],"Neoplasms","Solid Tumors","HER2 Positive Solid Tumor","Endometrial Neoplasm","Urothelial Carcinoma (UC)","Pancreatic Neoplasms","Colorectal Neoplasms","Head and Neck Neoplasms","Cervical Neoplasms","Ovarian Neoplasms",[27,36,37],"Zanidatamab","Basket Study","NOT_YET_RECRUITING","2026-06-02",{"date":41,"type":42},"2026-06-08","ACTUAL",{"date":44,"type":19},"2026-06-15",{"date":46,"type":19},"2029-12-31",{"name":48,"class":49},"Haihua Yuan","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":20,"phases":58,"briefSummary":59,"conditions":60,"keywords":71,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100643697","phase-2-exploratory-study-on-the-efficacy-and-safety-of-trastuzumab-rezetecan-in-the-treatment-of-her2-expressiong-advanced-solid-tumor-100643697","NCT07631884","Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor","Inclusion Criteria:\n\n1. Male and female participants aged 18 years or older.\n2. Participants with locally advanced, unresectable or metastatic solid tumors who have progressed after at least one prior systemic therapy for advanced\u002Fmetastatic disease, or have no satisfactory alternative treatment options. Eligible tumor types include but are not limited to biliary tract cancer, endometrial cancer, urothelial carcinoma, pancreatic cancer, colorectal cancer, gastric cancer, non-small cell lung cancer, head and neck adenocarcinoma (salivary gland adenocarcinoma, lacrimal gland adenocarcinoma, adenocarcinoma of unknown primary in the neck), cervical cancer, ovarian cancer and adenocarcinoma of unknown primary. Breast cancer is excluded.\n3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.\n4. Confirmed HER2 expression defined as IHC 1+, 2+ or 3+ (per GC criteria).\n5. Willing and able to provide adequate tumor specimens for central pathological re-testing of HER2 status. For participants previously treated with anti-HER2 therapy, tumor specimens obtained after the last anti-HER2 treatment are optional.\n6. At least one measurable lesion at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n7. Adequate organ and bone marrow function within 14 days prior to enrollment, meeting the following criteria:\n\n   Hemoglobin ≥ 9 g\u002FdL; Platelet count ≥ 100,000\u002Fmm³; Absolute neutrophil count (ANC) ≥ 1500\u002Fmm³; Serum albumin ≥ 3.0 g\u002FdL; Prothrombin time (PT), activated partial thromboplastin time (aPTT) and International Normalized Ratio (INR) ≤ 1.5 × upper limit of normal (ULN); Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 × ULN; ≤ 5 × ULN for participants with liver metastases; Total bilirubin ≤ 1.5 × ULN for participants without liver metastases; ≤ 3 × ULN for participants with Gilbert's syndrome or liver metastases at baseline; Creatinine clearance ≥ 30 mL\u002Fmin (calculated by the Cockcroft-Gault formula)\n8. Left ventricular ejection fraction (LVEF) ≥ 50% assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days prior to enrollment.\n\nExclusion Criteria:\n\nParticipants meeting any of the following conditions are ineligible for this study:\n\n1. Presence of any severe and\u002For uncontrolled diseases:\n\n   * Poorly controlled blood pressure (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg); poorly controlled diabetes (fasting blood glucose \\[FBG\\] \\> 10 mmol\u002FL).\n   * Grade ≥ 2 myocardial ischemia, myocardial infarction, arrhythmia (QTc interval ≥ 470 ms), or Grade ≥ 2 congestive heart failure (per New York Heart Association \\[NYHA\\] classification).\n   * Active or uncontrolled severe infections (Grade ≥ 2 per NCI CTCAE) requiring systemic antibacterial, antifungal or antiviral therapy, including pulmonary tuberculosis.\n   * History of active tuberculosis.\n   * Uncontrolled ascites, pericardial effusion or pleural effusion requiring repeated drainage.\n2. Active hepatitis: Liver function not meeting the inclusion criteria. Hepatitis B: HBV DNA ≥ 2000 IU\u002FmL or ≥ 10\\^4 copies\u002FmL.Hepatitis C: HCV RNA ≥ 2000 IU\u002FmL or ≥ 10\\^4 copies\u002FmL. Participants with viral load below the above thresholds after nucleoside antiviral therapy are eligible. Chronic hepatitis B virus carriers with HBV DNA \\\u003C 10\\^4 IU\u002FmL must receive concurrent antiviral treatment throughout the study for enrollment.\n3. History of immunodeficiency diseases, including HIV positivity or other acquired\u002Fcongenital immunodeficiency disorders.\n4. History of allogeneic solid organ transplantation or allogeneic hematopoietic stem cell transplantation.\n5. Confirmed meningeal metastasis, spinal cord metastasis or spinal cord compression.\n6. Within 6 months prior to the first study drug administration, presence of esophageal gastric varices, severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, acute gastrointestinal bleeding, extensive intestinal resection (partial colectomy or extensive small bowel resection complicated with chronic diarrhea), Crohn's disease, ulcerative colitis or long-standing chronic diarrhea.\n7. Unhealed or poorly healing wounds, or active ulcers.\n8. Toxicities from prior anti-tumor therapy have not resolved to Grade 0 or 1 per NCI CTCAE version 5.0.\n9. Received major surgery, incisional biopsy or significant traumatic injury within 28 days before study treatment initiation; or with long-standing unhealed wounds or fractures.\n10. History of severe hypersensitivity reactions to monoclonal antibodies; known allergy to the active ingredients or excipients of the study drug.",{"count":57,"type":19},15,[22],"The goal of this clinical trial is to learn if Trastuzumab Rezetecan can treat advanced solid tumors with HER-2 expression in adult participants.\n\nThe main question it aims to answer is: What is the objective response rate of Trastuzumab Rezetecan in adult patients with HER-2 expressed advanced solid tumors? Participants will receive intravenous infusion of Trastuzumab Rezetecan on Day 1 of each 21-day treatment cycle. The dosage is 4.8 mg\u002Fkg per cycle; participants with a body weight of 85 kg or above will receive a fixed dose of 408 mg every 3 weeks.",[26,61,62,63,64,65,66,67,68,29,30,31,69,70,32,33],"Neoplasms (Cancer \u002F Tumors)","Advanced Malignant Solid Neoplasm","Locally Advanced Malignant Solid Neoplasm","Unresectable Malignant Solid Neoplasm","Metastatic Malignant Solid Neoplasm","HER2 Expression","Biliary Tract Neoplasms","Endometrial Neoplasms","Gastric Neoplasms","Non-Small Cell Lung Carcinoma (NSCLC)",[72,73,74],"HER2 expression","Trastuzumab Rezetecan","Advanced Solid Tumor",{"date":41,"type":42},{"date":44,"type":19},{"date":78,"type":19},"2028-12-31",{"name":48,"class":49},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":87,"minAge":16,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":20,"phases":91,"briefSummary":92,"conditions":93,"keywords":99,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":4},"100502610","phase-2-cadonilimab-plus-nab--paclitaxel-for-patients-with-recurrent-or-metastatic-cervical-cancer-resistant-to-immune-checkpoint-inhibitors-100502610","NCT05824494","Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors","A Single-arm, Open-label, Multicenter Phase II Study of Cadonilimab Combined With Nab -Paclitaxel in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Previously Treated With Immune Checkpoint Inhibitors","Inclusion Criteria:\n\n1. Subjects are autonomous and fully autonomous, understand and voluntarily sign a written informed consent within 30 days before enrollment.\n2. Age ≥ 18 and ≤ 75 years old on the date of signing the informed consent form, female.\n3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n4. Expected survival period ≥ 3 months.\n5. Persistent, recurrent or metastatic cervical cancer confirmed by histology or cytology.\n6. Subjects who have previously failed treatment with PD-1, PD-L1 or CTLA4 inhibitors.\n7. There is at least one measurable tumor lesion according to the RECIST v1.1 standard; tumor lesions in the previous radiotherapy area or other locoregional treatment sites are generally not regarded as measurable lesions, unless the lesion has definite progression and persists after 3 months of radiotherapy, Or the tumor nature of the lesion is confirmed by biopsy.\n8. All subjects need to provide informed consent to provide freshly obtained tumor tissue samples or tumor tissue samples archived within 5 years (formalin-fixed paraffin-embedded \\[FFPE\\] tissue wax blocks or at least 5 unstained tumor tissue Biopsy samples, preferably freshly obtained tumor tissue samples). If the subject cannot provide the tumor tissue sample archived within 5 years before randomization or the tumor tissue sample is not suitable for use, a biopsy must be performed to collect fresh tumor tissue; if the investigator judges that there is a safety risk in the subject's tumor tissue biopsy, the Discuss with medical monitor.\n9. The subject agrees to collect tumor tissue and peripheral blood samples required during the screening period and the research process and apply them to relevant research.\n10. The results of laboratory tests after the screening period suggest that the subject has good organ function:\n\n    1. Hematology (no blood components and cell growth factor supportive treatment are allowed within 2 weeks before randomization): i. The absolute value of neutrophils ANC ≥ 1.5 × 109\u002FL (1,500\u002Fmm3); ii. Platelet count ≥ 100 × 109\u002FL (100,000\u002Fmm3); iii. Hemoglobin ≥ 90 g\u002FL.\n    2. Kidneys: i. Calculated creatinine clearance\\* (CrCl) ≥ 50 mL\u002Fmin\n\n       \\* CrCl will be calculated using the Cockcroft-Gault formula (Cockcroft-Gault formula) CrCl (mL\u002Fmin) = {(140 - age) × body weight (kg) × 0.85}\u002F (serum creatinine. (mg\u002FdL) × 72) ii. Urinary protein \\\u003C 2+ or 24-hour (h) urine protein quantitative \\\u003C 1.0 g.\n    3. Liver: i. Serum total bilirubin (TBil) ≤ 1.5 × ULN ii. AST and ALT ≤ 2.5× ULN iii. Serum albumin (ALB) ≥ 28 g\u002FL\n    4. coagulation function: i. International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (if the subject is receiving anticoagulant therapy, the subject must receive a stable dose of anticoagulant and coagulation parameters at the time of screening (PT\u002FINR and APTT) were within expected ranges with anticoagulant therapy).\n    5. Cardiac function: i. Left ventricular ejection fraction (LVEF) ≥ 50%.\n11. Female subjects of childbearing potential must have a serum pregnancy test within 3 days before the first dose and the result is negative. If a female subject of childbearing potential has sex with an unsterilized male partner, the subject must use an acceptable and effective method of contraception since screening and must agree to continue using these precautions until after the last dose of the study drug 6 months; Periodic abstinence and rhythm contraception are unacceptable contraceptive methods.\n\n    1. Females of childbearing potential are defined as females who have not been surgically sterilized (i.e. bilateral tubal ligation, bilateral oophorectomy, or total hysterectomy) or who have not undergone menopause (menopause is defined as at least Menopause for 12 consecutive months, serum follicle-stimulating hormone level is within the laboratory reference range for postmenopausal women);\n    2. A highly effective contraceptive method is one that has a low rate of contraceptive failure (eg, less than 1% per year) when used correctly and consistently. Not all birth control methods are equally effective. Female subjects of childbearing potential must use barrier contraception or hormonal contraception (such as oral contraceptives) to ensure that pregnancy does not occur.\n12. The subjects are willing and able to comply with the schedule of visits, treatment plans, laboratory tests, and other requirements of the study.\n\nExclusion Criteria:\n\n1. Suffering from other active malignant tumors within 3 years before randomization, except locally curable tumor types and those who have been cured, such as Squamous cell carcinoma of the skin, basal cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the breast.\n2. Severe immunotherapy-related toxicity occurred during the previous anti-PD-1\u002FPD-L1 monoclonal antibody treatment, including but not limited to: grade 3\u002F4 pneumonia, proteinuria, uveitis or episcleritis, myasthenia gravis, Pancreatitis, hepatitis, bullous skin disease (including SJS, TEN); grade 2-4 encephalitis, myocarditis; any grade of Guillain-Barré syndrome, transverse myelitis; severe inflammation that significantly affects the quality of life of the patient sex joints.\n3. Received chemotherapy, radiotherapy, biological therapy, endocrine therapy, immunotherapy, or other unmarketed clinical research drugs and other anti-tumor treatments within 4 weeks before the first use of the study drug.\n4. Received nab-paclitaxel drug therapy within 6 months before the first use of the study drug. Known contraindications to nab-paclitaxel or hypersensitivity to any of its components.\n5. Received drugs with immunomodulatory effects (such as thymosin, interferon, interleukin-2) within 2 weeks before randomization; received Chinese patent medicines with anti-tumor indications (such as Aidi injection, etc.) within 2 weeks before randomization.\n6. Received major organ surgery (not including needle biopsy, etc.) or experienced significant trauma within 4 weeks before the first use of the study drug, or required elective surgery during the trial\n7. There is central nervous system metastasis or cancerous meningitis.\n8. Pleural effusion, pericardial effusion, or peritoneal effusion with uncontrollable need for repeated drainage (more than once a month) of subjects.\n9. Suffering from active or recurrent autoimmune diseases; except the following: vitiligo, alopecia, psoriasis, or eczema that do not require systemic treatment; hypothyroidism caused by autoimmune thyroiditis that only requires stable doses of Hormone replacement therapy; type 1 diabetes requiring only a steady dose of insulin replacement therapy.\n10. Subjects who need to use \\> 10 mg\u002Fday prednisone or equivalent dose of glucocorticoid or other immunosuppressive drugs for systemic treatment within 14 days before randomization; except the following\n\n    1. Inhaled, ophthalmic or topical glucocorticoid therapy with a dose of ≤ 10 mg\u002Fday prednisone or equivalent dose is allowed.\n    2. Physiological glucocorticoid replacement therapy, with a dose of ≤ 10 mg\u002Fday prednisone or an equivalent dose of glucocorticoid.\n    3. Glucocorticoids as prophylaxis for hypersensitivity reactions (eg, before CT examination).\n11. Live vaccines have been used within 4 weeks before randomization.\n12. Known primary or secondary immunodeficiency, including human immunodeficiency virus (HIV) antibody test positive.\n13. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.\n14. Known history of interstitial lung disease or non-infectious pneumonia.\n15. Serious infection occurred within 4 weeks before randomization, including but not limited to complications requiring hospitalization, sepsis or severe pneumonia.\n16. There are active infections that require systemic treatment (including active tuberculosis and active Treponema pallidum infection), and have used systemic antibacterial, antiviral or antifungal drugs within 2 weeks before randomization; Note: for type B Antiviral drugs used for viral hepatitis are excluded.\n17. Active hepatitis B subjects, inactive or asymptomatic hepatitis B virus (HBV) carriers (hepatitis B surface antigen \\[HBsAg\\] positive) and HBV DNA\\> 1000 IU\u002FmL), and subjects with active hepatitis C virus.\n18. Suffering from active or documented inflammatory bowel disease (such as Crohn's disease, ulcerative colitis), active diverticulitis. There are clinical manifestations of gastrointestinal obstruction, or routine parenteral fluid rehydration, parenteral nutrition, or indwelling gastric tube are required.\n19. Any of the following cardiovascular and cerebrovascular diseases:\n\n    1. Myocardial infarction, unstable angina, pulmonary embolism, aortic dissection, deep venous thrombosis and any arterial thromboembolic events occurred within 6 months before randomization;\n    2. Heart failure with New York Heart Association (NYHA) functional class ≥ II;\n    3. There are severe arrhythmias that require long-term drug intervention; patients with atrial fibrillation who are asymptomatic and have stable ventricular rates are allowed;\n    4. Cerebrovascular events (CVA) occurred within 6 months before randomization;\n    5. Left ventricular ejection fraction (LVEF) \\\u003C 50%;\n    6. Previous history of myocarditis or cardiomyopathy.\n    7. Hypertension (defined as systolic blood pressure \\> 150 mmHg, diastolic blood pressure \\> 100 mmHg) that remains uncontrolled after adequate antihypertensive drug treatment, or a history of hypertensive crisis or hypertensive encephalopathy.\n\n       20\\) Known history of severe hypersensitivity to other monoclonal antibodies. 21) NCI CTCAE v5.0 ≥ grade 3 peripheral neuropathy exists. 22) The toxicity of previous anti-tumor therapy has not been relieved, defined as the toxicity has not recovered to NCI CTCAE v5.0 ≤ 2 grades, or the level specified in the inclusion\u002Fexclusion criteria (except hair loss) 23) The investigator believes that it may lead to risk of receiving the study drug treatment, or any condition that will interfere with the evaluation of the study drug or the safety of the subjects or the interpretation of the study results (such as suffering from other serious diseases or mental diseases, etc.).\n\n       24\\) Enroll in another clinical study at the same time, unless it is an observational, non-interventional clinical study or follow-up period of an interventional study.\n\n       25\\) Pregnant or lactating women. 26) Subjects considered by the investigator to be inappropriate to participate in the trial due to other reasons.","FEMALE","75 Years",{"count":90,"type":19},58,[22],"This is a phase II trial of combination therapy of cadonilimab(Bispecific Anti-PD-1\u002FCTLA-4 Antibody) plus nab-Paclitaxel in patients with recurrent or metastatic cervical cancer that had failed PD-1\u002FPD-L1 blockade therapy. As a bispecific antibody against PD-1 and CTLA-4, cardonirimab can not only induce the production of a large number of T cells in the early stage of immune response by antagonizing CTLA-4, but also block PD-1 and PD-L1\u002FL2 combination. Thereby restoring the killing function of T cells to tumor cells and reducing the exhaustion of T cells.The hypothesis is the combination of cadonilimab and nab-Paclitaxel will overcome PD-1\u002FPD-L1 blockade-resistance to enhance the response of patients with persistant, recurrent or metastatic cervical cancer.",[94,95,96,33,97,98],"Uterine Cervical Neoplasms","Cancer of Cervix","Cervical Cancer","Uterine Cervical Cancer","Cancer of the Uterine Cervix",[100,101],"PD-1","immune checkpoint inhibitor","2023-05-04",{"date":104,"type":42},"2023-05-06",{"date":106,"type":19},"2023-06",{"date":108,"type":19},"2026-06",{"name":110,"class":49},"Women's Hospital School Of Medicine Zhejiang University"]